drugset / Trial / NCT04081337

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

NCT04081337

Phase 1 Completed 55 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.

Timeline

Start
2020-07-09
Primary completion
2022-05-26
Completion
2022-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 15 mg Subcutaneous

Indications